doi: 10.1001/jama.2019.12662.
Angiotensin Receptor-Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction
Affiliations
- PMID: 31475298
- DOI: 10.1001/jama.2019.12662
Item in Clipboard
Angiotensin Receptor-Neprilysin Inhibition (ARNI) Therapy and Reverse Remodeling in Heart Failure With Reduced Ejection Fraction
JAMA.
.
No abstract available
Similar articles
-
Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure.JAMA Cardiol. 2016 Sep 1;1(6):714-7. doi: 10.1001/jamacardio.2016.1724. JAMA Cardiol. 2016. PMID: 27437874
-
Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction.Int J Cardiol. 2019 Apr 15;281:179-185. doi: 10.1016/j.ijcard.2018.05.124. Epub 2018 Jun 2. Int J Cardiol. 2019. PMID: 29891240 Review.
-
Should Angiotensin Receptor Neprilysin Inhibitors Replace Angiotensin-converting Enzyme Inhibitors in Heart Failure With a Reduced Ejection Fraction?Card Fail Rev. 2016 May;2(1):47-50. doi: 10.15420/cfr.2016:2:2. Card Fail Rev. 2016. PMID: 28785452 Free PMC article.
-
Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.Curr Atheroscler Rep. 2016 Aug;18(8):48. doi: 10.1007/s11883-016-0603-4. Curr Atheroscler Rep. 2016. PMID: 27324636 Review.
-
Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.Curr Heart Fail Rep. 2020 Jun;17(3):67-76. doi: 10.1007/s11897-020-00458-y. Curr Heart Fail Rep. 2020. PMID: 32394149 Review.
Cited by
-
Heart Failure With Improved Ejection Fraction: Prevalence, Predictors, and Guideline-Directed Medical Therapy.Cureus. 2024 Jun 6;16(6):e61790. doi: 10.7759/cureus.61790. eCollection 2024 Jun. Cureus. 2024. PMID: 38975458 Free PMC article. Review.
-
Sudden cardiac death prevention in the era of novel heart failure medications.Am Heart J Plus. 2023 Feb 24;27:100281. doi: 10.1016/j.ahjo.2023.100281. eCollection 2023 Mar. Am Heart J Plus. 2023. PMID: 38511092 Free PMC article. Review.
-
Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice.BMC Nephrol. 2022 Aug 23;23(1):293. doi: 10.1186/s12882-022-02919-z. BMC Nephrol. 2022. PMID: 35999504 Free PMC article.
-
A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis.Indian Heart J. 2021 Mar-Apr;73(2):211-213. doi: 10.1016/j.ihj.2021.01.002. Epub 2021 Jan 6. Indian Heart J. 2021. PMID: 33865520 Free PMC article.
-
Immunomodulation by systemic administration of human-induced pluripotent stem cell-derived mesenchymal stromal cells to enhance the therapeutic efficacy of cell-based therapy for treatment of myocardial infarction.Theranostics. 2021 Jan 1;11(4):1641-1654. doi: 10.7150/thno.46119. eCollection 2021. Theranostics. 2021. PMID: 33408772 Free PMC article.
LinkOut - more resources
Full Text Sources
